Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10, Rm. 9C-103, 10 CENTER DR MSC 1804, Bethesda, MD 20892-1804, USA.
Dig Dis Sci. 2011 Jan;56(1):139-54. doi: 10.1007/s10620-010-1234-1. Epub 2010 Aug 20.
Some patients with Zollinger-Ellison syndrome post curative gastrinoma resection continue to show gastric acid hypersecretion; however, the mechanism is unknown.
The aim of this study was to prospectively study acid secretion following curative gastrinoma resection and analyze factors contributing in patients with Zollinger-Ellison syndrome.
Fifty patients cured post gastrinoma resection were studied with serial assessments of acid secretory status, cure status and ECL-cell status/activity (with serial biopsies, CgA, urinary N-MIAA). Correlative analysis was performed to determine predictive factors.
Hypersecretion occurred in 31 patients (62%) and 14 had extreme-hypersecretion. There was an initial decline (3-6 months) in BAO/MAO, which then remained stable for eight years. Preoperative BAO correlated with the postoperative secretion, but not other clinical, tumoral, laboratory variables, the degree of postoperative acid suppression or type of antisecretory drug needed. Hypersecretors had greater postoperative ECL changes (P=0.005), serum CGA (P=0.009) and 24-h urinary N-MIAA (P=0.0038).
Post curative resection, gastric hypersecretion persists long term (mean 8 years) in 62% of patients and in 28% it is extreme, despite normogastrinemia. No preoperative variable except BAO correlates with postresection hypersecretion. The persistent increased ECL-cell extent post curative resection suggests prolonged hypergastrinemia can lead to changes in ECL-cells that are either irreversible in humans or sustained by unknown mechanisms not involving fasting hypergastrinemia and which can result in hypersecretion, in a proportion of which it can be extreme. Whether similar findings may occur in patients with idiopathic GERD treated for prolonged periods (>10 years) with PPIs, at present, is unknown.
一些 Zollinger-Ellison 综合征患者在治愈性胃泌素瘤切除术后仍表现出胃酸过度分泌;然而,其机制尚不清楚。
本研究旨在前瞻性研究治愈性胃泌素瘤切除术后胃酸分泌情况,并分析 Zollinger-Ellison 综合征患者的相关因素。
对 50 例治愈性胃泌素瘤切除术后患者进行研究,通过连续评估胃酸分泌状态、治愈状态和 ECL 细胞状态/活性(连续活检、CgA、尿 N-MIAA)进行分析。进行相关分析以确定预测因素。
31 例(62%)患者发生高分泌,14 例患者发生极度高分泌。BAO/MAO 最初下降(3-6 个月),然后稳定 8 年。术前 BAO 与术后分泌相关,但与其他临床、肿瘤、实验室变量、术后酸抑制程度或所需抗分泌药物类型无关。高分泌者术后 ECL 变化更大(P=0.005),血清 CGA(P=0.009)和 24 小时尿 N-MIAA(P=0.0038)。
治愈性切除术后,62%的患者长期(平均 8 年)存在胃酸过度分泌,其中 28%为极度分泌,尽管胃泌素水平正常。除 BAO 外,术前无其他变量与术后高分泌相关。治愈性切除术后 ECL 细胞持续增加提示长期高胃泌素血症可导致 ECL 细胞发生变化,这些变化在人类中可能是不可逆的,或者是由不涉及空腹高胃泌素血症的未知机制维持的,这些变化可能导致高分泌,其中一部分可能是极度的。目前尚不清楚在目前情况下,接受长期(>10 年)PPIs 治疗的特发性 GERD 患者是否会出现类似的发现。